Experts predict that COVID-19 may evolve into a mild respiratory illness, similar to the common cold, as our immune systems adapt through vaccinations and reinfections.
In November 2020, Catherine Smallwood, WHO Emergency Manager for Europe, stated: "The virus is with us forever." This tempered hopes for a swift return to normalcy amid nearly 100 million cases. A January 12, 2021, study in Science by researchers from Emory University and Pennsylvania State University suggests the pandemic may persist but could stabilize. They foresee SARS-CoV-2 becoming as benign as the common cold.
This shift requires widespread immunity via vaccines or prior infections, allowing the virus to circulate at low levels. The timeline hinges on the pace of population-wide infection and vaccination.
Drawing from six human coronaviruses—including four that cause colds, plus SARS (2003) and MERS (2012)—researchers note SARS-CoV-2's pattern: initial infections in children aged 3-5, becoming milder in adults.
Epidemiologist Romulus Breban of Institut Pasteur echoed this in an August 2020 La Croix interview, urging health systems to persevere. He likened COVID-19 to seasonal flu: persistent yet managed through vaccination and global surveillance, no longer an existential threat.
